L65.2
Alopecia mucinosa
Clinical Classification Guidelines
Medical Intelligence & Overview
Alopecia mucinosa, also known as follicular mucinosis, is a rare skin condition that affects the hair follicles, leading to hair loss and skin changes. It is characterized by the accumulation of mucin—a jelly-like substance—in the hair follicles, which may result in hair thinning or bald patches. Although often benign, alopecia mucinosa can sometimes be associated with other skin diseases or lymphomas. Recognizing the features of this condition is important for proper management and diagnosis.
Causes & Symptoms
Clinical Causes: Unknown exact cause in many cases, but it involves abnormal immune responses. Possible association with certain lymphomas, particularly cutaneous T-cell lymphoma. Associated with other skin conditions like dermatitis or eczema. Potential genetic predisposition in some individuals. Environmental factors are not well understood but may play a role. In some instances, it appears as a primary condition without underlying disease.
Key Symptoms: Localized or widespread hair loss, often forming patches. Presence of reddish, firm, or inflamed skin on the scalp or affected areas. Papules or plaques that may be tender or itchy. Areas of skin that are thickened or show abnormal texture. Sometimes, lesions exhibit a reddish or pinkish hue, especially in the early stages. Possible changes in hair texture or abnormal hair shedding.
Diagnostic & Treatment
Diagnosis Path: A skin biopsy is performed to examine tissue under a microscope, revealing mucin accumulation within hair follicles. Histopathological analysis can differentiate alopecia mucinosa from other hair loss conditions. Additional tests may include blood work to rule out related systemic diseases or lymphoma. Immunohistochemical staining may be used to identify atypical lymphocytes if lymphoma is suspected.
Treatment Protocols: Topical corticosteroids to decrease skin inflammation. Retinoids or other medications to promote skin healing. Phototherapy techniques such as PUVA (psoralen plus ultraviolet A therapy). Systemic therapies, including immunosuppressants or chemotherapy, if associated with lymphoma. Monitoring and follow-up for potential progression or association with malignancy. Addressing any underlying skin or systemic conditions that may coexist.
Clinical Advice & FAQs
Billing Guidance
Is L65.2 a billable ICD-10 code?
Yes, L65.2 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report L65.2?
Clinical documentation must specify the nature of Alopecia mucinosa and any associated comorbidities for accurate reporting.
Cite this Clinical Reference